Annual Report 2024

2024 was a pivotal year in both the global response to antimicrobial resistance and for ICARS. This report shares highlights from ICARS’ action-packed year, including:

• an update on ICARS’ rapidly growing project portfolio (55 projects in 25 countries and territories),
• emerging results from four projects nearing completion,
• a round-up of advocacy efforts from high-level meetings, to appearances in documentary-style programmes,
• an overview of ICARS’ multiple new capacity-strengthening initiatives,
• new Mission, Implementation, and Funding Partners,
• a summary of organisational developments,
• financial results,
• audit reports,
• an executive summary from the co-development review.

“Now, more than ever, it is essential to remain focused on identifying and implementing high-impact, cost-effective AMR solutions, an area where ICARS has consistently led the way since its inception. In the face of complex global challenges, our commitment to driving meaningful change through sustainable approaches, in collaboration with partners, remains unwavering.” – Sujith J. Chandy, Executive Director, ICARS